PE20160155A1 - Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos - Google Patents
Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activosInfo
- Publication number
- PE20160155A1 PE20160155A1 PE2015002430A PE2015002430A PE20160155A1 PE 20160155 A1 PE20160155 A1 PE 20160155A1 PE 2015002430 A PE2015002430 A PE 2015002430A PE 2015002430 A PE2015002430 A PE 2015002430A PE 20160155 A1 PE20160155 A1 PE 20160155A1
- Authority
- PE
- Peru
- Prior art keywords
- preferentially
- laba
- compositions
- salt
- glycopyronium
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 2
- 229960001664 mometasone Drugs 0.000 abstract 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 abstract 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001800 adrenalinergic effect Effects 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003060 bambuterol Drugs 0.000 abstract 1
- 229960004495 beclometasone Drugs 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229950010713 carmoterol Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001117 clenbuterol Drugs 0.000 abstract 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 abstract 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004993 dimenhydrinate Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- 229960000193 formoterol fumarate Drugs 0.000 abstract 1
- 229950001768 milveterol Drugs 0.000 abstract 1
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 229960004017 salmeterol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPOSIONES FARMACEUTICAS EN SUSPENSION QUE COMPRENDE UNA COMBINACION FIJA DE AL MENOS TRES INGREDIENTES ACTIVOS: UN ANTAGONISTA MUSCARINICO DE ACCION PROLONGADA (LAMA), UN AGONISTA BETA-2 ADRENERGICO DE ACCION PROLONGADA (LABA) Y UN CORTICOSTEROIDE INHALABLE (ICS). DICHAS COMPOSICIONES PUEDEN FORMULARSE PARA EL SUMINISTRO POR VIA RESPIRATORIA A TRAVES DE UN INHALADOR DE DOSIS MEDIDA (MDI). EL AGENTE ACTIVO LABA SE SELECCIONA ENTRE BAMBUTEROL, CLENBUTEROL, FORMOTEROL, SALMETEROL, CARMOTEROL O MILVETEROL, ENTRE OTROS; PREFERENTEMENTE UNA SAL DE FORMOTEROL Y MAS PREFERENTEMENTE, FUMARATO DE FORMOTEROL. EL AGENTE ACTIVO LAMA SE SELECCIONA ENTRE GLICOPIRRONIO, DEXIPIRRONIO, ESCOPOLAMINA, DIMENHIDRINATO, TIOTROPIO, IPATROPIO, ATROPINA, ENTRE OTROS; PREFERENTEMENTE UNA SAL DE GLICOPIRRONIO Y MAS PREFERENTEMENTE, BROMURO DE GLICOPIRRONIO. EL AGENTE ACTIVO ICS SE SELECCIONA ENTRE BECLOMETASONA, BUDESONIDA, FLUTICASONA, MOMETASONA, PREDNISONA, TRIAMCINOLONA, ENTRE OTROS; PREFERENTEMENTE UNA SAL O ESTER DE MOMETASONA O BUDESONIDA. TAMBIEN SE REFIERE A METODOS PARA LA PREPARACION DE DICHAS COMPOSICIONES FARMACEUTICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826424P | 2013-05-22 | 2013-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160155A1 true PE20160155A1 (es) | 2016-04-01 |
Family
ID=50942948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002430A PE20160155A1 (es) | 2013-05-22 | 2014-05-22 | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20150150787A1 (es) |
| EP (1) | EP2999460A1 (es) |
| JP (1) | JP2016519160A (es) |
| KR (1) | KR20160013134A (es) |
| CN (1) | CN105392471A (es) |
| AU (1) | AU2014268482A1 (es) |
| BR (1) | BR112015028964A2 (es) |
| CA (1) | CA2912927A1 (es) |
| CL (1) | CL2015003422A1 (es) |
| CR (1) | CR20150645A (es) |
| DO (1) | DOP2015000284A (es) |
| HK (2) | HK1221653A1 (es) |
| MX (1) | MX2015016058A (es) |
| NI (1) | NI201500163A (es) |
| PE (1) | PE20160155A1 (es) |
| PH (1) | PH12015502593A1 (es) |
| RU (1) | RU2015154720A (es) |
| SG (1) | SG11201509543YA (es) |
| WO (1) | WO2014190204A1 (es) |
| ZA (1) | ZA201509016B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3111926T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego |
| BR122016004924A2 (pt) * | 2012-03-09 | 2019-07-30 | Pfizer Inc. | Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos |
| WO2015077574A1 (en) * | 2013-11-22 | 2015-05-28 | Teva Branded Pharmaceutical Products R&D, Inc. | An inhalable medicament |
| SI3191081T1 (sl) | 2014-09-09 | 2020-07-31 | Vectura Limited | Formulacija, ki vsebuje glikopirolat, postopek in naprava |
| TW201735914A (zh) * | 2015-12-22 | 2017-10-16 | 阿斯特捷利康公司 | 用於治療慢性阻塞性肺疾病之醫藥組成物 |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| CN114712338A (zh) | 2016-09-19 | 2022-07-08 | 墨西哥氟石股份公司 | 药物组合物 |
| WO2019142214A1 (en) | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
| WO2020123057A2 (en) * | 2018-10-31 | 2020-06-18 | Repurposed Therapeutics, Inc. Dba Defender | Treatment of exposure to chlorine gas with scopolamine |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN111349036B (zh) * | 2020-03-13 | 2022-03-08 | 安徽恒星制药有限公司 | 一种格隆溴铵的替代物及其制备方法和医药用途 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| CN111617138A (zh) * | 2020-07-07 | 2020-09-04 | 上海凯宝药业股份有限公司 | 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用 |
| CR20240064A (es) | 2021-07-09 | 2024-09-02 | Astrazeneca Pharmaceuticals Lp | Composiciones, métodos y sistemas para la administración de fármacos en aerosol |
| US20250057764A1 (en) * | 2021-12-20 | 2025-02-20 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| AU706195B2 (en) | 1995-04-14 | 1999-06-10 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| US5886200A (en) | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| PT102343B (pt) | 1999-08-02 | 2003-11-28 | Hovione Farmaciencia Sa | Processo para a preparacao de furoato mometasona |
| ES2343124T3 (es) | 1999-10-29 | 2010-07-23 | Novartis Ag | Composiciones de polvo seco con dispersabilidad mejorada. |
| US7862834B2 (en) | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
| EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
| PL3111926T3 (pl) * | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| EP2749283A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and olodaterol |
| CN103687483A (zh) * | 2011-05-17 | 2014-03-26 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
-
2014
- 2014-05-22 PE PE2015002430A patent/PE20160155A1/es not_active Application Discontinuation
- 2014-05-22 HK HK16109865.5A patent/HK1221653A1/zh unknown
- 2014-05-22 CN CN201480041316.3A patent/CN105392471A/zh active Pending
- 2014-05-22 BR BR112015028964A patent/BR112015028964A2/pt not_active IP Right Cessation
- 2014-05-22 JP JP2016515104A patent/JP2016519160A/ja active Pending
- 2014-05-22 EP EP14730411.7A patent/EP2999460A1/en not_active Withdrawn
- 2014-05-22 US US14/285,435 patent/US20150150787A1/en not_active Abandoned
- 2014-05-22 KR KR1020157036274A patent/KR20160013134A/ko not_active Withdrawn
- 2014-05-22 SG SG11201509543YA patent/SG11201509543YA/en unknown
- 2014-05-22 WO PCT/US2014/039234 patent/WO2014190204A1/en not_active Ceased
- 2014-05-22 RU RU2015154720A patent/RU2015154720A/ru not_active Application Discontinuation
- 2014-05-22 HK HK16109866.4A patent/HK1221654A1/zh unknown
- 2014-05-22 AU AU2014268482A patent/AU2014268482A1/en not_active Abandoned
- 2014-05-22 CA CA2912927A patent/CA2912927A1/en not_active Abandoned
- 2014-05-22 MX MX2015016058A patent/MX2015016058A/es unknown
-
2015
- 2015-11-16 PH PH12015502593A patent/PH12015502593A1/en unknown
- 2015-11-20 NI NI201500163A patent/NI201500163A/es unknown
- 2015-11-20 CL CL2015003422A patent/CL2015003422A1/es unknown
- 2015-11-20 DO DO2015000284A patent/DOP2015000284A/es unknown
- 2015-12-08 CR CR20150645A patent/CR20150645A/es unknown
- 2015-12-10 ZA ZA2015/09016A patent/ZA201509016B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150645A (es) | 2016-02-10 |
| BR112015028964A2 (pt) | 2017-07-25 |
| CN105392471A (zh) | 2016-03-09 |
| WO2014190204A1 (en) | 2014-11-27 |
| CA2912927A1 (en) | 2014-11-27 |
| NI201500163A (es) | 2016-01-06 |
| RU2015154720A (ru) | 2017-06-27 |
| KR20160013134A (ko) | 2016-02-03 |
| HK1221654A1 (zh) | 2017-06-09 |
| ZA201509016B (en) | 2018-07-25 |
| DOP2015000284A (es) | 2016-04-29 |
| US20150150787A1 (en) | 2015-06-04 |
| CL2015003422A1 (es) | 2016-09-02 |
| EP2999460A1 (en) | 2016-03-30 |
| AU2014268482A1 (en) | 2016-01-07 |
| PH12015502593A1 (en) | 2016-02-29 |
| MX2015016058A (es) | 2016-12-20 |
| JP2016519160A (ja) | 2016-06-30 |
| HK1221653A1 (zh) | 2017-06-09 |
| SG11201509543YA (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| AR130239A2 (es) | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada | |
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| CO6290637A2 (es) | Composicion farmaceutica que comprende aclidinio en forma de un polvo seco de una sal farmaceuticamente aceptable mezclado con un vehiculode polvo seco farmaceuticamente aceptable | |
| PE20080204A1 (es) | Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista | |
| AR080747A1 (es) | Proceso para preparar particulas de vehiculo para polvos secos para inhalacion | |
| HRP20180944T1 (hr) | Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola | |
| AR079726A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes | |
| HRP20231729T1 (hr) | Kombinirana terapija za kopb | |
| UY35199A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3 | |
| JP2019528316A5 (es) | ||
| PE20141703A1 (es) | Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion | |
| HRP20200537T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| AR106687A1 (es) | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO | |
| MX2015007912A (es) | Inhalador de polvo seco y metodo de uso. | |
| MX2012004338A (es) | Formulaciones mejoradas. | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| CL2016002848A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
| JP2015522025A5 (es) | ||
| JP2014527056A5 (es) | ||
| BR112015027247A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas | |
| AR088273A1 (es) | Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida | |
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| Gelb et al. | Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |